Design of highly potent anti-biofilm, antimicrobial peptides using explainable artificial intelligence

Karina Pikalyova,Tagir Akhmetshin,Alexey Orlov,Evan F. Haney,Noushin Akhoundsadegh,Jiaying You,Robert E.W. Hancock,Dragos Horvath,Gilles Marcou,Artem Cherkasov,Alexandre Varnek
DOI: https://doi.org/10.1101/2024.11.17.622654
2024-11-18
Abstract:Antimicrobial peptides have emerged as a potential alternative to traditional small molecule antibiotics. They possess broad-spectrum efficacy and increasingly confront the challenges of bacterial resistance, especially the adaptive resistance of biofilms. However, advanced rational peptide design methods are still required to ensure optimal property profiles of such peptides, while limiting the cost of their synthesis and screening. Here we present a computational pipeline for the rational de novo design of antimicrobial and anti-biofilm peptides based on an explainable artificial intelligence (XAI) framework. The developed framework combines a Wasserstein Autoencoder (WAE) and a non-linear dimensionality reduction method termed generative topographic mapping (GTM). The WAE was used to learn the latent representation of the peptide space, while the GTM guided the generation of novel AMPs through an illustrative depiction of the latent space in the form of 2D maps. The efficacy of the peptides generated with the developed pipeline was experimentally verified by synthesis and testing for activity against methicillin resistant Staphylococcus aureus (MRSA), achieving a 100% hit rate in targeting biofilms. Notably, the most potent anti-biofilm peptide developed in this study demonstrated almost one order of magnitude improvement in IC50 value compared with the potent anti-biofilm peptide reference '1018', used as a positive control. The developed pipeline is readily extendable for the optimization of additional peptide properties, including cytotoxicity, tendency to aggregate and proteolytic stability, underscoring its potential utility for rational design of the peptide-based therapeutics.
Bioinformatics
What problem does this paper attempt to address?